IFP Advisors’s Cyclo Therapeutics, Inc. Common Stock CYTH Stock Holding History

IFP Advisors’s Portfolio CYTH Stock Details CYTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-13	Closed	-$18	–	3385
2023 Q3	$18	Hold	13	–	–	﹤0.01%	3264
2023 Q2	$21	Hold	13	–	–	﹤0.01%	3419
2023 Q1	$55	Hold	13	–	–	﹤0.01%	3323
2022 Q4	$1K	Hold	13	–	–	﹤0.01%	4534
2022 Q3	$1K	Hold	13	–	–	﹤0.01%	4723
2022 Q2	$1K	Hold	13	–	–	﹤0.01%	4490
2022 Q1	$1K	Hold	13	–	–	﹤0.01%	4488
2021 Q4	$1K	Hold	13	–	–	﹤0.01%	3156
2021 Q3	$1K	Hold	13	–	–	﹤0.01%	3170
2021 Q2	$0	Buy	+13	New	+$109	﹤0.01%	3273

Other funds holding CYTH

FFVM

Founders Fund V Management San Francisco, California $2.16M AUM 77.37% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

FFVM

Founders Fund VI Management San Francisco, California $45.8K AUM 58.63% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

IFP Advisors's CYTH Position: Q4 2023 in Review

IFP Advisors sold out of Cyclo Therapeutics, Inc. Common Stock (CYTH) in Q4 2023, closing a stake of 13 shares — an estimated $18 sold.

IFP Advisors first reported a position in CYTH in Q2 2021 and held it in 10 quarters. The position peaked at $1K in Q4 2022. 23 funds tracked by Wall St. Rank hold CYTH as of Q4 2023.

IFP Advisors reported no remaining Cyclo Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
IFP Advisors sold 13 Cyclo Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $18.
IFP Advisors first reported a position in Cyclo Therapeutics, Inc. Common Stock in Q2 2021 and held it in 10 quarters.
IFP Advisors's Cyclo Therapeutics, Inc. Common Stock position peaked at $1K in Q4 2022.
23 funds tracked by Wall St. Rank held Cyclo Therapeutics, Inc. Common Stock as of Q4 2023.

Based on IFP Advisors's 13F filing for Q4 2023, filed 9 Jan 2024.